U.S. FDA approves Daiichi anti-clotting drug

January 9, 2015 12:00 AM

16 0

(Reuters) - U.S. regulators on Thursday approved the use of a drug made by Daiichi Sankyo Co Ltd to reduce the risk of stroke and blood clots in patients with an irregular heartbeat not caused by a heart valve problem.

The new drug, Savaysa, will compete with older blood thinners, including Xarelto, sold by Bayer AG and Johnson & Johnson, Boehringer Ingelheim's Pradaxa, and Bristol-Myers Squibb Co's Eliquis.

Read more

To category page